Search
Research
Toll-like receptor 2 ligands inhibit Th2 responses to mite allergenThere is intense interest in the interaction between microbial compounds and allergy.
Research
Toward improved prediction of risk for atopy and asthma among preschoolers: A prospective cohort studyAtopy and asthma are commonly initiated during early life, and there is increasing interest in the development of preventive treatments for at-risk children.
Research
UV exposure and protection against allergic airways diseaseAsthma is a chronic inflammatory disease of the small and large conducting airway mucosa characterised by Th2 cell immunity.
News & Events
NHMRC funding awarded to support child health researchThe Kids Research Institute Australia researchers have been awarded more than $10 million in research funding from the National Health and Medical Research Council (NHMRC).
News & Events
Switch on the immune system earlyFindings by Professor Pat Holt revealed researchers had been heading down the wrong path in their battle strategy against respiratory allergy and asthma.
News & Events
Overseas trip will help unlock the asthma puzzleOne in ten Australians have asthma and Dr Kimberley Wang from The Kids Research Institute Australia is on a mission to find out what causes it.
News & Events
Volunteers needed for world-first trial to prevent asthmaAustralian scientists have today launched a world first research trial into a treatment that could prevent asthma in high risk children.
Research
Global change, climate change, and asthma in children: Direct and indirect effects - A WAO Pediatric Asthma Committee ReportThe twenty-first century has seen a fundamental shift in disease epidemiology with anthropogenic environmental change emerging as the likely dominant factor affecting the distribution and severity of current and future human disease. This is especially true of allergic diseases and asthma with their intimate relationship with the natural environment.
Research
Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case seriesEnsitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited.
Research
Respiratory infection- and asthma-prone, low vaccine responder children demonstrate distinct mononuclear cell DNA methylation pathwaysnfants with frequent viral and bacterial respiratory infections exhibit compromised immunity to routine immunizations. They are also more likely to develop chronic respiratory diseases in later childhood. This study investigated the feasibility of epigenetic profiling to reveal endotype-specific molecular pathways with potential for early identification and immuno-modulation.